Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kaoru Tsuchiya

Showing results (51-60 of 149) with videos related to

Pageof 15
Sort By:
Liver Cancer|August 18, 2015
JSH Consensus-Based Clinical Practice Guidelines for the Management of Hepatocellular Carcinoma: 2014 Update by the Liver Cancer Study Group of JapanMasatoshi Kudo, Osamu Matsui, Namiki Izumi, et al.
Journal of Hepatology|March 11, 2008
The presence of steatosis and elevation of alanine aminotransferase levels are associated with fibrosis progression in chronic hepatitis C with non-response to interferon therapyMasayuki Kurosaki, Kotaro Matsunaga, Itsuko Hirayama, et al.
Liver Cancer|May 16, 2024
Multicenter Phase II Trial of Lenvatinib plus Hepatic Intra-Arterial Infusion Chemotherapy with Cisplatin for Advanced Hepatocellular Carcinoma: LEOPARDMasafumi Ikeda, Tatsuya Yamashita, Sadahisa Ogasawara, et al.
Oncology|November 26, 2011
Early decrease in α-fetoprotein, but not des-γ-carboxy prothrombin, predicts sorafenib efficacy in patients with advanced hepatocellular carcinomaTeiji Kuzuya, Yasuhiro Asahina, Kaoru Tsuchiya, et al.
Hepatology (Baltimore, Md.)|August 5, 2010
Effect of aging on risk for hepatocellular carcinoma in chronic hepatitis C virus infectionYasuhiro Asahina, Kaoru Tsuchiya, Nobuharu Tamaki, et al.
Nihon Shokakibyo Gakkai Zasshi = the Japanese Journal of Gastro-Enterology|June 7, 2013
[A case of systemic amyloidosis with cholangiectasis diagnosed by liver biopsy]Yuji Kawano, Yutaka Yasui, Kaoru Tsuchiya, et al.
Plos One|June 19, 2018
Impact of pre-sarcopenia in sorafenib treatment for advanced hepatocellular carcinomaHitomi Takada, Masayuki Kurosaki, Hiroyuki Nakanishi, et al.
Liver Cancer|August 8, 2024
Impact of Bevacizumab Being Skipped due to Adverse Events of Special Interest for Bevacizumab in Patients with Unresectable Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab: An Exploratory Analysis of the Phase III IMbrave150 StudyMasatoshi Kudo, Kaoru Tsuchiya, Yu-Yun Shao, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|October 5, 2010
Hepatic steatosis in chronic hepatitis C is a significant risk factor for developing hepatocellular carcinoma independent of age, sex, obesity, fibrosis stage and response to interferon therapyMasayuki Kurosaki, Takanori Hosokawa, Kotaro Matsunaga, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|June 10, 2020
Validation of albumin, bilirubin, and platelet criteria for avoiding screening endoscopy in patients with advanced fibrosisNobuharu Tamaki, Masayuki Kurosaki, Mayu Higuchi, et al.
Pageof 15

Showing results (51-60 of 149) with videos related to

Sort By:
Pageof 15
Liver Cancer|August 18, 2015
JSH Consensus-Based Clinical Practice Guidelines for the Management of Hepatocellular Carcinoma: 2014 Update by the Liver Cancer Study Group of JapanMasatoshi Kudo, Osamu Matsui, Namiki Izumi, et al.
Journal of Hepatology|March 11, 2008
The presence of steatosis and elevation of alanine aminotransferase levels are associated with fibrosis progression in chronic hepatitis C with non-response to interferon therapyMasayuki Kurosaki, Kotaro Matsunaga, Itsuko Hirayama, et al.
Liver Cancer|May 16, 2024
Multicenter Phase II Trial of Lenvatinib plus Hepatic Intra-Arterial Infusion Chemotherapy with Cisplatin for Advanced Hepatocellular Carcinoma: LEOPARDMasafumi Ikeda, Tatsuya Yamashita, Sadahisa Ogasawara, et al.
Oncology|November 26, 2011
Early decrease in α-fetoprotein, but not des-γ-carboxy prothrombin, predicts sorafenib efficacy in patients with advanced hepatocellular carcinomaTeiji Kuzuya, Yasuhiro Asahina, Kaoru Tsuchiya, et al.
Hepatology (Baltimore, Md.)|August 5, 2010
Effect of aging on risk for hepatocellular carcinoma in chronic hepatitis C virus infectionYasuhiro Asahina, Kaoru Tsuchiya, Nobuharu Tamaki, et al.
Nihon Shokakibyo Gakkai Zasshi = the Japanese Journal of Gastro-Enterology|June 7, 2013
[A case of systemic amyloidosis with cholangiectasis diagnosed by liver biopsy]Yuji Kawano, Yutaka Yasui, Kaoru Tsuchiya, et al.
Plos One|June 19, 2018
Impact of pre-sarcopenia in sorafenib treatment for advanced hepatocellular carcinomaHitomi Takada, Masayuki Kurosaki, Hiroyuki Nakanishi, et al.
Liver Cancer|August 8, 2024
Impact of Bevacizumab Being Skipped due to Adverse Events of Special Interest for Bevacizumab in Patients with Unresectable Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab: An Exploratory Analysis of the Phase III IMbrave150 StudyMasatoshi Kudo, Kaoru Tsuchiya, Yu-Yun Shao, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|October 5, 2010
Hepatic steatosis in chronic hepatitis C is a significant risk factor for developing hepatocellular carcinoma independent of age, sex, obesity, fibrosis stage and response to interferon therapyMasayuki Kurosaki, Takanori Hosokawa, Kotaro Matsunaga, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|June 10, 2020
Validation of albumin, bilirubin, and platelet criteria for avoiding screening endoscopy in patients with advanced fibrosisNobuharu Tamaki, Masayuki Kurosaki, Mayu Higuchi, et al.
Pageof 15